A former pharmaceutical executive based out of Hillsborough, N.J., Dishant Gupta, has admitted to engaging in insider trading, according to an announcement from the U.S. Attorney's Office in Boston. The 40-year-old Gupta pled guilty to one count of securities fraud and faces a sentence that could reach up to 20 years in prison, in addition to fines that may total up to $5 million.
Reports indicate that while employed at a global pharmaceutical company, dubbed Company A, Gupta capitalized on confidential information regarding the company's impending acquisition of a smaller Boston-based pharmaceutical firm, identified as Company B. This acquisition included a leading cancer drug that had been Company B's flagship product. In an ill-gotten attempt to leverage this inside knowledge for personal gain, Gupta made purchases exceeding 300,000 shares of Company B's stock through his and his wife's brokerage accounts.
The U.S. District Court Judge Julia E. Kobick has scheduled a sentencing for Gupta on January 9, 2025. The U.S. Attorney’s Office indicated that the defendant cashed in all his shares following Company A's public announcement of acquiring Company B, profiting Gupta more than $250,000. The serious charges reflect the severity of manipulating the market and breaching fiduciary duties for personal enrichment.
Moreover, the Securities and Exchange Commission has filed a civil complaint alleging securities laws violations by Gupta. The federal case is being prosecuted by Assistant U.S. Attorney Benjamin A. Saltzman of the Securities, Financial & Cyber Fraud Unit, with Acting United States Attorney Joshua S. Levy and Special Agent in Charge of the Federal Bureau of Investigations, Boston Division, Jodi Cohen leading the announcement. This case serves as a stringent reminder of the consequences of exploiting privileged information in financial markets.
